NVO

Now let's talk about Novo, formerly known as Novo Nordisk. The company's shares are under pressure this morning. The market appears to be dissatisfied with the plan revealed by Novo regarding its strategy for the next phase.

It is clear that they saw a large demand for their weight loss drug, at least in its early stages. But now, competition has entered this field and captured part of their market share.

All right. And last but not least, we look at Novo Nordisk. I saw a downgrade and a price target below where we are now.